Format

Send to

Choose Destination
Curr Opin Infect Dis. 2007 Feb;20(1):11-5.

HIV and pneumococcal disease.

Author information

1
Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, USA. keith.klugman@emory.edu

Abstract

PURPOSE OF REVIEW:

To describe the impact of highly active antiretroviral therapy on the burden of pneumococcal disease and advances in our understanding of the impact of HIV on this disease.

RECENT FINDINGS:

Although highly active antiretroviral therapy has reduced the burden of pneumococcal disease among HIV-infected adults, these infections remain far more common than in HIV uninfected adults. HIV-infected adults who smoke or have comorbidities are at particular risk. In the absence of highly active antiretroviral therapy, pneumococcal meningitis has emerged in Africa as a major disease burden with a high mortality among HIV-infected children and adults. Conjugate pneumococcal vaccine protects HIV-infected infants from pneumococcal pneumonia. In the United States, where conjugate vaccine is given to children, herd immunity has reduced the burden of invasive pneumococcal disease among HIV-infected adults.

SUMMARY:

The pneumococcus remains a significant cause of morbidity and mortality among HIV-infected children and adults, both in developed and in developing countries.

PMID:
17197876
DOI:
10.1097/QCO.0b013e328012c5f1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center